Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Pacritinib

Drug and asset intelligence for Pacritinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Recent signals(1)

ClinicalJuly 2, 2026

Phase I Trial of Pacritinib with Venetoclax and Azacitidine for Myeloproliferative Neoplasms

A Phase I trial is investigating the combination of pacritinib, venetoclax, and azacitidine for treating accelerated and blast phase myeloproliferative neoplasms.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Pacritinib

Monitor trial results for safety and efficacy, as well as potential regulatory filings based on outcomes.

July 2, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Hematology · Myeloproliferative Neoplasms →

Myeloproliferative Neoplasms →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.